Patient recruitment companies compared: which model fits your trial?
By Bryan Manning, Founder · Updated August 2026
Direct answer: There’s no single “best” patient recruitment company. There are five different business models, and the right one depends on your therapeutic area, timeline, and how much enrollment risk you want to carry. Marketplaces sell you access to pre-registered patients. Ad agencies sell you campaigns. Patient communities sell you reach into specific conditions. Data companies sell you EHR-based patient finding. Success-based firms (our model) sell you enrolled patients and carry the risk themselves. This page compares all five honestly, including where each one beats us.
Why we wrote a comparison that includes our competitors
Most “top recruitment companies” lists are written by recruitment companies that put themselves at the top. We’re doing the same thing with one difference: we’ll tell you when a competitor’s model is a better fit than ours. If your trial needs what a marketplace does well, hiring us for it would be a mistake, and mistakes in recruitment cost trials months.
The five models
1. Patient access marketplaces
Examples: SubjectWell, Antidote
These companies maintain large registries of people who’ve raised their hand for research, then match them to trials. SubjectWell runs a global patient access marketplace with multi-channel digital recruitment and a clinically trained contact center. Antidote operates a large opt-in patient database with condition-specific matching.
Strong when: you need volume fast in common conditions (diabetes, dermatology, general population studies) and your sites can handle high referral flow.
Weak when: criteria are narrow, the condition is rare, or your sites are already drowning in unqualified referrals. Marketplaces are typically paid per referral or randomization, and referral quality varies.
2. Digital advertising specialists
Examples: StudyKIK, Trial AMPlify
Campaign-driven recruitment: social ads, landing pages, pre-screeners, referral tracking. StudyKIK is known for social media advertising and mobile tools connecting patients to trials.
Strong when: the patient population is reachable on social platforms and you have internal capacity to manage screening and site handoff.
Weak when: nobody owns what happens after the click. Ad-driven referrals that no one calls back within a day mostly evaporate. If you buy ads without buying follow-through, you’re paying for traffic, not patients.
3. Patient communities and precision platforms
Examples: Sano Genetics, Inspire, Rare Patient Voice
Built around engaged patient populations, often with genetic testing or longitudinal engagement layered in. Sano Genetics connects patient identification, genetic testing, and long-term engagement in one platform.
Strong when: you need genetically qualified patients or deep engagement in a specific rare disease community.
Weak when: your condition doesn’t have an existing engaged community, or you need speed over depth.
4. Data and EHR mining
Examples: Deep 6 AI, TriNetX, Tempus
These find patients who already exist in health records, using EHR and real-world data to identify candidates at specific health systems.
Strong when: the eligible population is well documented in structured data and concentrated at large health systems.
Weak when: eligibility depends on things records don’t capture, or identified patients still need someone to actually reach out, screen, and schedule them. Finding a patient in a database is not the same as enrolling them.
5. Success-based, full-ownership recruitment
That’s us: Clinical Enrollment
We take ownership of the entire path: identification, double-screening, scheduling, and follow-through to the site visit, and we only get paid for enrolled patients. Not clicks. Not referrals. Enrollments. Until the agreed number is hit, the financial risk is ours.
Two numbers tell you how that plays out. Starting at trial launch, we typically deliver 32% of a phase 2 or phase 3 trial’s total enrollment, and we’ve been as high as 47%. And 89% of the patients we send to a site go on to sign the consent form, because nobody gets there without being screened twice and walked in by a human.
Strong when: enrollment is the make-or-break risk on your trial, criteria are hard, sites are stretched, or you’ve been burned by referral volume that never converted. Our sponsor programs have averaged $19.2M in savings and finished enrollment 57 days ahead of plan, with an 18% reduction in screen fails.
Weak when: you genuinely just need cheap top-of-funnel volume for an easy-to-fill study. A marketplace will cost you less.
Comparison table
| You pay for | Risk sits with | Best fit | |
|---|---|---|---|
| Marketplaces (SubjectWell, Antidote) | Referrals/randomizations | Shared | Common conditions, volume |
| Ad specialists (StudyKIK) | Campaigns + referrals | Sponsor | Reachable populations, strong internal ops |
| Communities (Sano, Inspire) | Access + engagement | Sponsor | Rare disease with engaged communities |
| Data mining (Deep 6, TriNetX) | Patient identification | Sponsor | EHR-documented populations at large systems |
| Success-based (Clinical Enrollment) | Enrolled patients only | Vendor | Hard criteria, tight timelines, high enrollment risk |
Questions to ask any recruitment vendor
- What exactly do I pay for: impressions, referrals, screens, or enrollments?
- Who calls the patient back, and how fast? (Ask for their median first-contact time.)
- What’s your screen-fail rate on trials like mine?
- What happens to your fee if you miss the enrollment target?
- Can I talk to a sponsor whose trial was behind when you took over?
The last two questions are where most vendor conversations get quiet. Nearly 85% of interventional trials miss enrollment milestones, yet almost every RFP response promises on-time delivery. We call that the overpromise gap, and the only honest fix we’ve found is putting our own fee at risk.
Frequently asked questions
What does patient recruitment cost?
Depends entirely on the model and the condition. Marketplaces and ad models charge per referral or per randomization; costs per enrolled patient in competitive indications commonly run into the tens of thousands of dollars once screen fails are counted. Success-based pricing prices the enrolled patient directly, so the quoted number is the real number.
What’s the difference between recruitment and enrollment?
Recruitment gets a patient interested. Enrollment gets them screened, qualified, consented, and randomized. The gap between the two is where most trials lose their timeline, and most vendors are only accountable for the first half.
Should I use a recruitment company or let my CRO handle it?
CROs manage trials; recruitment is usually a subcontracted line item, not their core muscle. If enrollment is your biggest risk, a specialist accountable specifically for enrollment numbers is usually worth the added vendor. If your CRO’s plan is “sites will handle it,” ask what happens at month three when they haven’t.
Enrollment on the line?
Most firms recruit patients. We deliver enrollments. We take ownership of the whole path, from first click to site visit, and we only get paid when patients enroll.